TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial
Brief Summary: Fibromyalgia (FMS) is a syndrome expressed by chronic widespread body pain which leads to reduced physical function and frequent use of health care services. Exercise training is commonly recommended as a treatment.

The purpose of this study is to determine whether a supervised resistance muscular exercise (RME) and walking program (WP) are effective in the treatment of FMS on decrease of pain.

The practical of the RME reduces the pain of participants with FMS.


Options:
A: Arm Label: Tai Chi; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lower frequency, shorter period of Tai Chi, Behavioral: Higher frequency, shorter period of Tai Chi, Behavioral: Shorter frequency, longer period of Tai Chi, Behavioral: Higher frequency, longer period of Tai Chi | Arm Label: Aerobic Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic Exercise Training | Intervention Type: BEHAVIORAL; Name: Lower frequency, shorter period of Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Higher frequency, shorter period of Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Shorter frequency, longer period of Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Higher frequency, longer period of Tai Chi; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Training; Assigned to Arm(s): Aerobic Exercise Training
B: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise
C: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
D: Arm Label: Group education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group education | Arm Label: 8-form Yang-style Tai chi program; Type: EXPERIMENTAL; Interventions: Behavioral: 8-form Yang-style Tai chi | Intervention Type: BEHAVIORAL; Name: 8-form Yang-style Tai chi; Assigned to Arm(s): 8-form Yang-style Tai chi program | Intervention Type: BEHAVIORAL; Name: Group education; Assigned to Arm(s): Group education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial
Brief Summary: Fibromyalgia (FMS) is a syndrome expressed by chronic widespread body pain which leads to reduced physical function and frequent use of health care services. Exercise training is commonly recommended as a treatment.

The purpose of this study is to determine whether a supervised resistance muscular exercise (RME) and walking program (WP) are effective in the treatment of FMS on decrease of pain.

The practical of the RME reduces the pain of participants with FMS.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle physical activity (LPA) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fibromyalgia education | Intervention Type: BEHAVIORAL; Name: Lifestyle physical activity (LPA); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Fibromyalgia education; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
C: Arm Label: CFQ Qigong training group; Type: ACTIVE_COMPARATOR; Interventions: Other: CFQ Qigong | Intervention Type: OTHER; Name: CFQ Qigong; Assigned to Arm(s): CFQ Qigong training group
D: Arm Label: Strength training; Type: EXPERIMENTAL; Interventions: Behavioral: Strength training | Arm Label: Aerobic exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Strength training; Assigned to Arm(s): Strength training | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Physical Exercise on Decrease of Pain in Patients With Fibromyalgia:Randomized Clinical Trial
Brief Summary: Fibromyalgia (FMS) is a syndrome expressed by chronic widespread body pain which leads to reduced physical function and frequent use of health care services. Exercise training is commonly recommended as a treatment.

The purpose of this study is to determine whether a supervised resistance muscular exercise (RME) and walking program (WP) are effective in the treatment of FMS on decrease of pain.

The practical of the RME reduces the pain of participants with FMS.


Options:
A: Arm Label: Interdisciplinary treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Interdisciplinary treatment, Behavioral: Interdisciplinary treatment of fibromyalgia | Arm Label: Usual treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment; Assigned to Arm(s): Interdisciplinary treatment | Intervention Type: BEHAVIORAL; Name: Interdisciplinary treatment of fibromyalgia; Assigned to Arm(s): Interdisciplinary treatment
B: Intervention Type: BEHAVIORAL; Name: walking program, resistance muscular exercise; Assigned to Arm(s): N/A
C: Arm Label: A. High intensive exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Physical exercise | Arm Label: B. Low-intensive exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Active comparator: low intensive exercise | Intervention Type: BEHAVIORAL; Name: Physical exercise; Assigned to Arm(s): A. High intensive exercise | Intervention Type: BEHAVIORAL; Name: Active comparator: low intensive exercise; Assigned to Arm(s): B. Low-intensive exercise
D: Arm Label: water-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: water-based exercise | Arm Label: land-based exercise intervention; Type: EXPERIMENTAL; Interventions: Behavioral: land-based exercise intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: water-based exercise; Assigned to Arm(s): water-based exercise intervention | Intervention Type: BEHAVIORAL; Name: land-based exercise intervention; Assigned to Arm(s): land-based exercise intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cardiovascular Risk Factors in Veterans With Bipolar Disorder
Brief Summary: The purpose of this research study is to learn whether or not people with bipolar disorder can reduce their risk of heart disease and related conditions by having a Care Manager provide self management and care management.


Options:
A: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
B: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Reverse Colocated Integrated Care | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: Reverse Colocated Integrated Care; Assigned to Arm(s): Intervention Group | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Control Group
C: Arm Label: Collaborative shared care; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative shared care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Collaborative shared care | Intervention Type: BEHAVIORAL; Name: Collaborative shared care; Assigned to Arm(s): Collaborative shared care, Usual care
D: Arm Label: Chronic Care Model for Bipolar Disorder; Type: EXPERIMENTAL; Interventions: Behavioral: Chronic care model for Bipolar Disorder | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Chronic care model for Bipolar Disorder; Assigned to Arm(s): Chronic Care Model for Bipolar Disorder

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD
Brief Summary: Assess the efficacy \& tolerability of Vyvanse when children aged 6-12 years diagnosed with ADHD are dosed to optimal effect.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIIb, Randomized, Double-Blind, Multi-Center, Placebo- Controlled, Dose-Optimization, Cross-Over, Analog Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention-Deficit/Hyperactivity Disorder
Brief Summary: The primary objective of this study is to assess the time of onset of Vyvanse compared to placebo, in the analog classroom as measured by the Swanson, Kotkin, Agler, M. Flynn and Pelham (SKAMP) deportment scale in children (aged 6-12) diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).


Options:
A: Intervention Type: DRUG; Name: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate; Assigned to Arm(s): N/A
B: Arm Label: Lisdexamfetamine Dimesylate (LDX) 30 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 30 mg | Arm Label: LDX 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 50 mg | Arm Label: LDX 70 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: LDX 70 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LDX 30 mg; Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) 30 mg | Intervention Type: DRUG; Name: LDX 50 mg; Assigned to Arm(s): LDX 50 mg | Intervention Type: DRUG; Name: LDX 70 mg; Assigned to Arm(s): LDX 70 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Lisdexamfetamine Dimesylate (LDX); Type: EXPERIMENTAL; Interventions: Drug: Lisdexamfetamine Dimesylate (LDX) | Arm Label: Methylphenidate Hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Hydrochloride | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lisdexamfetamine Dimesylate (LDX); Assigned to Arm(s): Lisdexamfetamine Dimesylate (LDX) | Intervention Type: DRUG; Name: Methylphenidate Hydrochloride; Assigned to Arm(s): Methylphenidate Hydrochloride | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vyvanse (lisdexamfetamine dimesylate) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vyvanse (lisdexamfetamine dimesylate); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Effect of Inhaled Aclidinium Bromide (LAS34273) 200 ug on Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe COPD
Brief Summary: This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD. It was 9 weeks in duration, consisting of; a 2-week run-in period, 6 weeks of double-blind treatment, and a 1-week follow-up phone call. All patients meeting the eligibility criteria were randomized to one of two treatment groups: aclidinium bromide or placebo.


Options:
A: Arm Label: Aclidinium bromide 200 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 200 μg bid | Arm Label: Aclidininum bromide 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 200 μg bid; Assigned to Arm(s): Aclidinium bromide 200 μg bid | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidininum bromide 400 μg bid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2
C: Arm Label: Aclidinium 200 μg once-daily; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): Aclidinium 200 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Aclidinium; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium Bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium Bromide; Assigned to Arm(s): Aclidinium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
Brief Summary: This is a multicenter study designed to compare the effect of exenatide plus a lifestyle modification plan versus placebo plus a lifestyle modification plan on weight loss in non-diabetic, obese subjects.


Options:
A: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: exenatide | Arm Label: Group B; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Group B
B: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Saxagliptin; Type: EXPERIMENTAL; Interventions: Drug: Saxagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized Trial of Chemoradiation With or Without Panitumumab in Subjects With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Brief Summary: The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed. The study is investigating if the addition of a targeted therapy (panitumumab) can improve the efficacy of chemoradiation without adding unmanageable toxicity.


Options:
A: Arm Label: CETUXIMAB AND DASATINIB; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: Dasatinib | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): CETUXIMAB AND DASATINIB | Intervention Type: DRUG; Name: Dasatinib; Assigned to Arm(s): CETUXIMAB AND DASATINIB
B: Arm Label: Lapatinib; Type: EXPERIMENTAL; Interventions: Drug: Lapatinib oral tablets, Drug: radiotherapy, Drug: cisplatin chemotherapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lapatinib oral tablets, Drug: radiotherapy, Drug: cisplatin chemotherapy | Intervention Type: DRUG; Name: Lapatinib oral tablets; Assigned to Arm(s): Lapatinib, Placebo | Intervention Type: DRUG; Name: radiotherapy; Assigned to Arm(s): Lapatinib, Placebo | Intervention Type: DRUG; Name: cisplatin chemotherapy; Assigned to Arm(s): Lapatinib, Placebo
C: Arm Label: Afatinib (BIBW 2992); Type: EXPERIMENTAL; Interventions: Drug: Afatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Afatinib; Assigned to Arm(s): Afatinib (BIBW 2992)
D: Arm Label: Panitumumab Plus Chemoradiation; Type: EXPERIMENTAL; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy, Drug: Panitumumab | Arm Label: Chemoradiotherapy Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Radiation: Standard Fractionation Radiotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: RADIATION; Name: Standard Fractionation Radiotherapy; Assigned to Arm(s): Chemoradiotherapy Alone, Panitumumab Plus Chemoradiation | Intervention Type: DRUG; Name: Panitumumab; Assigned to Arm(s): Panitumumab Plus Chemoradiation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Acute Intravenous Magnesium Loading on Pulmonary Function Parameters and Maximal Exercise Capacity of Patients With Chronic Obstructive Pulmonary Disease in Stable Clinical Conditions.
Brief Summary: Dietary magnesium (Mg) intake has been shown to be independently related to lung function, airway reactivity, and respiratory symptoms in the general population. Inhaled Mg and IV Mg administration have been shown to promote bronchodilation and to improve lung function in asthmatic patients. Some studies have suggested that COPD patients exhibit decreased body levels of Mg. The purpose of the present study was to investigate the effects of acute IV Mg loading on parameters of respiratory function and maximal exercise capacity of stable COPD patients.The study hypothesis is that Mg administration will be associated to improvements on airflow and vasodilation leading to improvements of pulmonary function and exercise performance.


Options:
A: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
B: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
C: Arm Label: Mg-group; Type: EXPERIMENTAL; Interventions: Drug: Magnesium Sulphate | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Magnesium Sulphate; Assigned to Arm(s): Mg-group
D: Intervention Type: DRUG; Name: Magnesium Sulfate 2 grams; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Real Time Continuous Glucose Monitoring System (RT-CGMS) in Type 1 Diabetes Patients on Continuous Intraperitoneal Insulin Infusion (CIPII. A Feasibility Study
Brief Summary: To investigate the effectiveness and safety of a Real Time Continuous Glucose Monitoring System (RT-CGMS in a population of patients with type 1 diabetes mellitus treated with insulin through an implanted pump.


Options:
A: Arm Label: Conventional insulin pump therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Minimed Paradigm 512/712 Insulin pump | Arm Label: Minimed paradigm Real Time Sytem; Type: EXPERIMENTAL; Interventions: Device: Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed paradigm Real Time Sytem; Assigned to Arm(s): Minimed paradigm Real Time Sytem | Intervention Type: DEVICE; Name: Minimed Paradigm 512/712 Insulin pump; Assigned to Arm(s): Conventional insulin pump therapy
B: Arm Label: A,1; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Arm Label: A,2; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Intervention Type: DEVICE; Name: Real time access to current glucose values during CGMS; Assigned to Arm(s): A,1, A,2
C: Arm Label: Open; Type: EXPERIMENTAL; Interventions: Device: Real-Time Continuous Glucose monitoring System (RT-CGMS) | Arm Label: Blind; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Real-Time Continuous Glucose monitoring System (RT-CGMS); Assigned to Arm(s): Open
D: Arm Label: 722 sensor augmented pump; Type: EXPERIMENTAL; Interventions: Device: MiniMed Paradigm REAL-Time System | Arm Label: Multiple Daily Injections (MDI); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MiniMed Paradigm REAL-Time System; Assigned to Arm(s): 722 sensor augmented pump

Answer: C